3Q23 & 9M23 Performance Overview

CLINICS & DIAGNOSTICS BUSINESS OPERATING PERFORMANCE OVERVIEW REVENUE DEVELOPMENT² CLINICS & DIAGNOSTICS KEY DRIVERS The y-o-y increase in total revenues in 3Q23 is attributable to higher demand for non-COVID regular ambulatory services and the expansion of the business. ■ Similar to the hospitals business, the new facility regulation, also affected community clinics. In certain departments, admissions were temporarily suspended due to renovation works. ☐ In 3Q23, the business sold one of its polyclinic buildings for US$ 6.2 million. The gain from this transaction amounted to GEL 2.9 million. GEL MILLION 19 +7.9% 20 20 4 14 16 3Q22 3Q23 ■Clinics Diagnostics - Total KEY OPERATING HIGHLIGHTS 99 65 -1.3% 65 16 13 51 49 EBITDA¹ DEVELOPMENT GEORGIA CAPITAL +33.8% 11 NMF 8 1 5 10 7 1 5 9M22 9M23 3Q22 3Q23 9M22 9M23 ■Clinics Diagnostics Clinics 3Q22 VS. ■ 3Q23 Change y-o-y 9M22 VS. ■ 9M23 Number of admissions ('000) Number of registered patients ('000) Diagnostics 1,619.8 1,481.8 Change y-o-y -8.5% 483.8 460.3 -4.9% 608.3 632.2 +3.9% 608.3 632.2 +3.9% Number of patients served ('000) Number of total tests performed ('000) 208 501 164 -20.9% +11.8% 762 560 1,799 577 1,810 -24.3% +0.6% Georgia Capital PLC 1. Excluding IFRS 16. 2. Total revenue excludes eliminations between the clinics & diagnostics business lines. 72

View entire presentation